Senju Pharma has launched a new drug for dry eye disease (DED) in Japan, Avarept, which is the first drug in the TRPV1 antagonist class to reach the market. Licensed from fellow Japanese drugmaker ...

Three years after buying Bellus Health and its chronic cough candidate camlipixant for around $2 billion, GSK is abandoning ...

For decades, pharmaceutical marketing has been built on a simple premise: if we present the right data, to the right audience ...

In the biggest venture capital financing this week, clinical-stage radiopharmaceutical AdvanCell has closed a $315 million ...

The European Commission has approved Novo Nordisk's pill formulation of weight-loss therapy Wegovy, making it the first oral ...

Mission Therapeutics of the UK has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, ...

All 15-year-old children in the UK should be offered the vaccine against meningitis B (MenB) in the wake of fatal outbreaks ...

Any uncertainty about whether the second Trump administration would prioritise healthcare fraud enforcement was put to rest ...

MSD has won the race to bring an oral PCSK9 inhibitor through to regulatory approval in the US, after getting the go-ahead ...

Thousands of people in England and Wales with a type of chronic heart failure (CHF) could soon be eligible for treatment with ...

After a delay, Eisai and Biogen have won FDA approval for their new subcutaneous formulation of Alzheimer's disease therapy ...